Biodegradable stents: The golden future of angioplasty?

The Lancet

Volumn 385, Issue 9962, 2015, Pages 10-12

  Di Mario, Carlo ^a,b   Caiazzo, Gianluca ^b  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; RAPAMYCIN;

ANGIOPLASTY; BIODEGRADABLE STENT; BIORESORBABLE SCAFFOLD; HUMAN; INTRAVASCULAR ULTRASOUND; METAL STENT; NOTE; STENT; STENT THROMBOSIS; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BIODEGRADABLE IMPLANT; DRUG ELUTING STENT; FEMALE; MALE; MYOCARDIAL ISCHEMIA; TISSUE SCAFFOLD;

ABSORBABLE IMPLANTS; DRUG-ELUTING STENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MYOCARDIAL ISCHEMIA; SIROLIMUS; TISSUE SCAFFOLDS;

EID: 84920430817     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61636-6     Document Type: Note

References (17)

1. R Erbel, C Di Mario, J Bartunek et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial Lancet 369 2007 1869 1875
2. M Haude, R Erbel, P Erne et al. Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial Lancet 381 2013 836 844
3. JA Ormiston, PW Serruys, E Regar et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial Lancet 371 2008 899 907
4. PW Serruys, JA Ormiston, Y Onuma et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods Lancet 373 2009 897 910
5. PW Serruys, B Chevalier, D Dudek et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial Lancet 2014 published online Sept 14. http://dx.doi.org/10.1016/S0140-6736(14)61455-0
6. RP Kraak, ME Hassell, MJ Grundeken et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: the AMC Single Centre Real World PCI Registry EuroIntervention 2014 10.4244/EIJY14M08-08 published online Aug 20.
7. D Capodanno, T Gori, H Nef et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry EuroIntervention 2014 10.4244/EIJY14M07-11 published online July 18.
8. RJ van Geuns EuroPCR2014 http://www.pcronline.com/Lectures/2014/BVS-Expand-6-month-results (accessed Sept 8, 2014).
9. V Koška, M Malý, P Toušek et al. Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19' Eur Heart J 35 2014 787 794
10. T Gori, E Schulz, U Hink et al. Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes EuroIntervention 9 2014 1036 1041
11. SH Kang, KW Park, DY Kang et al. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis Eur Heart J 35 2014 1147 1158
12. K Fujii, SG Carlier, GS Mintz et al. Stent underexpansion and residual reference segment stenosis are related to stent thrombosis after sirolimus-eluting stent implantation: an intravascular ultrasound study J Am Coll Cardiol 45 2005 995 998
13. H Doi, A Maehara, GS Mintz et al. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials JACC Cardiovasc Interv 2 2009 1269 1275
14. A Mattesini, GG Secco, G Dall'Ara et al. ABSORB biodegradable stents versus second-generation metal stents: a comparison study of 100 complex lesions treated under OCT guidance JACC Cardiovasc Interv 7 2014 741 750
15. AJ Brown, LM McCormick, DM Braganza, MR Bennett, SP Hoole, NE West Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation Catheter Cardiovasc Interv 84 2014 37 45
16. C Costopoulos, A Latib, T Naganuma et al. Comparison of early clinical outcomes between absorb bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population Catheter Cardiovasc Interv 2014 10.1002/ccd.25569 published online June 6.
17. Y Onuma, D Dudek, L Thuesen et al. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial JACC Cardiovasc Interv 6 2013 999 1009